Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease.

Jason M CastanedaTravis Hee WaiLaura J SpeceKevin I DuanAristotle LeonhardMatthew F GriffithRobert PlumleyBrian N PalenLaura C FeemsterDavid H AuLucas M Donovan

Published in: Annals of the American Thoracic Society (2023)

Among patients with COPD, we did not observe greater risks following new receipt of zolpidem relative to other hypnotics. However, we did observe greater risks relative to those without hypnotic receipt. This latter finding may reflect: 1) residual, unmeasured confounding related to insomnia, or, 2) true adverse effects of hypnotics across classes. Future work is needed to better understand the risks of hypnotics in COPD.

Keyphrases

human health
chronic obstructive pulmonary disease
risk assessment
emergency department
climate change
physical activity